TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The experienced participants who were treated previously with (SOF/DCV) , (SOF/SMV), (SOF/RBV), or (SOF/pegINF/RBV).~* The presence of compensated liver cirrhosis was documented by ultrasonographic examination, liver biopsy, results of Fibroscan or FIB-4 score, and laboratory markers, like FIB-4 \> 3.25 (advanced fibrosis or cirrhosis), albumin \< 3.5, total bilirubin \> 1.2, and also confirmed by clinical characteristics such as lower limb edema, splenomegaly, esophageal varices.~Exclusion Criteria:~* liver disease of non-HCV GT4 etiology, coinfection with hepatitis B or HIV~* poorly controlled diabetes (HbA1C \> 8)~* participants, hepatocellular carcinoma, a history of extrahepatic malignancy in the 5 years prior to the study~* renal failure~* evidence of hepatic decompensation~* blood picture abnormalities such as anemia (hemoglobin concentration of \< 10 g/dL)~* thrombocytopenia (platelets count \< 50,000 cells/mm3).~* major severe illness such as congestive heart failure and respiratory failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cirrhotic Participants (Type: ACTIVE_COMPARATOR): The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
- Non-cirrhotic Participants (Type: ACTIVE_COMPARATOR): The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven non-muscle invasive bladder cancer;~* Indication to intravesical instillation of BCG according to EAU guidelines;~* Age \> 18 years;~* Willingness, to participate to the study;~* Written informed consent.~Exclusion Criteria:~* Previous or ongoing BCG or different intravesical instillations;~* Urinary tract infections (UTI) or other known pathologies of the lower urinary tract;~* Indication for a radical cystectomy;~* Severe systemic disorders, including neurological pathologies, kidney, liver or heart failure;~* Contraindications to BCG use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BCG alone (Immucist®) (Type: ACTIVE_COMPARATOR): Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
- Hyaluronic acid (Type: EXPERIMENTAL): Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy.~* Cephalic presentation.~* Bishop score \< or = 6.~* Average size of the fetus.~* Adequate pelvic dimensions.~* Prelabour rupture of membranes.~* Term or post-term pregnancies with an indication for labor induction either maternal or fetal.~Exclusion Criteria:~* Previous uterine scar (e.g. caesarian delivery or unknown uterine incision , previous hysterotomy or myomectomy of the uterine corpus involving entry of the uterine cavity or extensive myometrial dissection, previous uterine rupture)~* Patients with regular uterine contractions.~* Malpresentation.~* Multifetal gesta1tion.~* Established fetal distress ( e.g. thick meconium stained liguor or non reassuring CTG changes)~* Indication for CS, e.g. Major degree of cephalopelvic disproportion and fetal macrosomia.~* Placenta previa or vasa previa.~* Active genital herpes infection.~* Severe maternal illness (e.g. severe preeclampsia).~* Laboratory and clinical sign of chorioamnionitis.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- isosorbide mono-nitrate group (Type: EXPERIMENTAL): 70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
- placebo group (Type: PLACEBO_COMPARATOR): 70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female with type 2 diabetes mellitus~2. 35 years old≤age≤65 years old~3. 19kg/m2≤BMI≤32kg/m2~4. Uncontrolled blood glycemia (FPG≥7.0mmol/L and 7.5%\<HbA1c≤10%) after oral antidiabetes drugs treatment for more than 3 months~5. Treated by diet controlling, 1 secretagogue agent and another oral antidiabetes drug, with the daily dosage of the secretagogue agent not more than 50% of its maximum~6. Not participated in other clinical studies within the past 3 months~7. Well know this study and sign the informed consent form~Exclusion criteria:~1. Unable to sign the informed consent form~2. Treated by insulin, even transient usage within the past 1 year~3. Type 1 diabetes mellitus~4. Abnormal condition of gastrointestinal tract against the absorption of oral drugs~5. Insufficient of liver and kidney function: ALT≥2.5 times of the upper limit of the normal value range and serum creatinine≥the upper limit of the normal value range~6. Encountered the cardiovascular events such as the angina pectoris, myocardial infarction, severe ventricular arrhythmia, cerebral hemorrhage, cerebral infarction, heart failure ect. within the past half year~7. Usage of the other hormone medicines such as cortical hormone, immunosuppressive agents or cytotoxic drugs within the past 2 months~8. psychotic~9. Allergic history to sulfonylurea drugs~10. Diabetic coma or diabetic ketoacidosis~11. In use of the miconazole~12. Pregnancy or breeding women

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Combination therapy (Type: EXPERIMENTAL): The subjects allocated into this arm will receive the combination therapy of oral administration of 60\~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
- monotherapy (Type: ACTIVE_COMPARATOR): The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of the GlideScope Ranger in Pediatric Critical Care Transport

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \< 18 years~* Presence of respiratory failure requiring tracheal intubation by the Critical Care Transport Team either at the referring institution or during the transport to the receiving institution~* Ability of parent or legal guardian to provide written informed consent~Exclusion Criteria:~* Patients 18+ years of age~* Patient has a functioning tracheostomy~* Patient does not require orotracheal intubation

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Intubation using GlideScope Ranger (Type: EXPERIMENTAL): The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
- intubation using direct laryngoscopy (Type: ACTIVE_COMPARATOR): The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Pyuria~* Have a pretreatment baseline urine culture obtained within 36 hours before the start of administration of the first dose of study drug~* Clinical signs and/or symptoms of acute pyelonephritis or complicated urinary tract infection~* Normal renal function or moderate renal impairment~Key Exclusion Criteria:~* Confirmed fungal urinary tract infection at the time of randomization~* Known urinary tract infection or colonization with Gram-positive pathogens~* Current cUTI or AP is known to be caused by a pathogen resistant to meropenem~* Female participants of childbearing potential if they are known to be pregnant or have a positive pregnancy test at screening, breastfeeding, or unable or unwilling to use a highly effective method of birth control during the study and for at least 30 days following the last dose of study medication~* Any rapidly progressing disease or immediately life-threatening illness~* Documented presence of immunodeficiency or an immunocompromised condition~* Documented or known history of otologic surgery or disease including use of hearing aid, head injury leading to otologic damage, Ménière's disease, tumor of the head, neck, or auditory system, perilymphatic fistula, or autoimmune disease of the inner ear, or family history of hearing loss (excluding age-related hearing loss \[onset after age of 65 years\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plazomicin (Type: EXPERIMENTAL): Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
- Meropenem (Type: ACTIVE_COMPARATOR): Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Screening plasma HIV-1 RNA ≥1000 c/mL~* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)~* Ability to understand and sign a written informed consent form~* Willingness to use approved methods of contraception to avoid pregnancy (women of child bearing potential only)~* Age equal to or greater than 18 years~Exclusion Criteria:~* Women who are pregnant or breastfeeding;~* Active Center for Disease and Prevention Control (CDC) Category C disease~* Moderate to severe hepatic impairment~* Anticipated need for HCV therapy during the study~* Allergy or intolerance to the study drugs or their components or drugs of their class~* Malignancy within the past 5 years~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening~* Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening~* Exposure to an agent with documented activity against HIV-1 in vitro or an experimental vaccine or drug within 28 days of first dose of study medication~* Primary viral resistance in the Screening result~* Verified Grade 4 laboratory abnormality~* ALT \>5 xULN~* ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with \>35% direct bilirubin);~* Estimated creatinine clearance \<50 mL/min~* Recent history (≤3 months) of upper or lower gastrointestinal bleed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1349572 (N=~394) (Type: EXPERIMENTAL): GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
- raltegravir (N=~394) (Type: ACTIVE_COMPARATOR): raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Health worker inclusion criteria:~* 18 years of age or older~* working full-time at one of the health facilities included in the study~* staff in Malawi's Assisted Contact Tracing program.~Health worker exclusion criteria:~* conditions that would compromise ability of participant to provide informed consent, undergo study procedures safely, or prevent proper conduct of study~Patient (index or contact) inclusion criteria:~-\>=15 years~-potential index, contact, or parent or guardian of a potential index or contact~Patient (index or contact) exclusion criteria:~* conditions that would compromise ability of individual to provide informed consent, undergo study procedures safely, or prevent proper conduct of study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enhanced implementation strategy (Type: EXPERIMENTAL): digitally guided training and continuous quality improvement
- Standard implementation strategy (Type: ACTIVE_COMPARATOR): standard training and clinical support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Morphologic evidence of acute myeloid leukemia in first relapse.~2. Phase I: 18 years or older, Phase II: 50 years or older~Exclusion Criteria:~1. Prior treatment with zosuquidar~2. Any investigational agent within 1 month of enrollment and lack of recovery from toxicities secondary to those agents~3. History of stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 years or above~* Patients scheduled for elective total knee replacement~Exclusion Criteria:~* Active bleeding or high risk of bleeding contraindicating treatment with Low Molecular Weight Heparin (LMWH)~* Contraindication listed in the labeling or conditions precluding subject treatment with enoxaparin or requiring dose adjustment (e.g. severe renal impairment, please refer to the local label of enoxaparin in your country)~* Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939)) (Type: EXPERIMENTAL): Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
- Enoxaparin 30 mg twice a day (bid) (Type: ACTIVE_COMPARATOR): Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A healthy male or female adult aged between 18 and 40 years.~* Written informed consent obtained from the subject~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Administration of a vaccine not foreseen by the study protocol within 14 days (killed vaccine) or 30 days (attenuated/ live vaccine) before the first vaccine dose.~* Concurrently participating in another clinical study or exposure to an investigational or a non-investigational product (pharmaceutical product or device).~* History of hepatitis B infection.~* Known exposure to hepatitis B virus within 6 months.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SOOTHER Trial to Treat Rectal Itch

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presence of pruritus ani (anal itch/discomfort) for at least 2 weeks, and a compatible physical exam.~Exclusion Criteria:~* Inability to understand informed consent, history of inflammatory bowel disease, known venereal disease, or immunodeficiency disease, history of or current anal or perianal abscess, anal or rectal surgery within the past 12 weeks, pregnancy or breastfeeding female, or signs of other rectal diseases such as anorectal fistula, infection, perianal eczema or tumors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pruritus ani patients (Type: None): Adult patients with pruritus ani (rectal itch) treated with lidocaine ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete